Target type: biologicalprocess
Any process that activates or increases the frequency, rate, or extent of a chronic inflammatory response to an antigenic stimulus. [GOC:add]
Positive regulation of chronic inflammatory response to antigenic stimulus is a complex biological process that involves a sustained and prolonged inflammatory response to a persistent antigen. It is characterized by the recruitment and activation of various immune cells, including macrophages, neutrophils, lymphocytes, and mast cells, leading to the release of pro-inflammatory cytokines, chemokines, and other mediators. This prolonged inflammation contributes to tissue damage and the development of chronic inflammatory diseases.
The process begins with the recognition of an antigen by antigen-presenting cells (APCs), such as dendritic cells and macrophages. These cells engulf and process the antigen, presenting it to T lymphocytes via major histocompatibility complex (MHC) molecules. This antigen presentation triggers the activation of T cells, leading to the production of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6. These cytokines, along with other signaling molecules, stimulate the recruitment and activation of other immune cells, such as neutrophils and macrophages.
Neutrophils, which are the first responders to inflammation, release cytotoxic molecules and proteases, contributing to tissue damage. Macrophages play a crucial role in phagocytosing pathogens and debris, as well as secreting inflammatory mediators. They also present processed antigen to T cells, further amplifying the inflammatory response.
The prolonged exposure to the antigen leads to the activation of Th17 cells, a subset of T helper cells that produce pro-inflammatory cytokines, primarily IL-17. IL-17 promotes the recruitment and activation of neutrophils and macrophages, contributing to the persistence of inflammation.
In addition to cytokines, chemokines play a role in the recruitment of immune cells to the site of inflammation. Chemokines, such as CCL2 and CXCL8, attract macrophages and neutrophils, respectively.
The chronic inflammatory response is characterized by the formation of granulomas, localized areas of inflammation containing immune cells and extracellular matrix. Granulomas are often associated with chronic infections and autoimmune diseases.
The dysregulation of various signaling pathways, including NF-κB, MAPK, and JAK-STAT, contributes to the persistence of inflammation. These pathways regulate the expression of genes involved in inflammation, including pro-inflammatory cytokines and chemokines.
The chronic inflammatory response is a critical defense mechanism against persistent pathogens, but it can also contribute to the development of various chronic diseases, including rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis. Understanding the molecular mechanisms underlying chronic inflammation is crucial for developing novel therapeutic strategies for treating these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Tumor necrosis factor | A tumor necrosis factor that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
way 151693 | |||
pentoxifylline | oxopurine | ||
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
ganoderic acid a | triterpenoid | ||
ganoderiol f | ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source | triterpenoid | |
1-(phenylmethyl)benzimidazole | benzimidazoles | ||
luteolin-7-glucoside | luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
apigetrin | apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. apigetrin: structure given in first source | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative | antibacterial agent; metabolite; non-steroidal anti-inflammatory drug |
calycosin-7-o-beta-d-glucopyranoside | calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. calycosin-7-O-beta-D-glucoside: from Radix Astragali | 4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative | |
spd-304 | SPD-304: structure in first source | ||
ganoderic acid f | ganoderic acid F: isolated from Ganoderma lucidum; structure in first source | triterpenoid | |
ganoderic acid c2 | ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source | triterpenoid |